Shenzhen Beike Biotechnology Co. Ltd., a Chinese stem cell research and regenerative medicine company, announced that it has invested in Yokohama-based Biomaster Inc., an innovator in the field of adipose-derived stem cell regenerative technology.
Beike, along with two investment companies, has taken a significant share in Biomaster, secured a seat on the board, and is involved in the company’s strategic positioning in preparation for an eventual IPO.
The proceeds from the investment will enable Biomaster to develop stem cell-based hair growth, spinal repair and organ regeneration therapies. The company will benefit from Beike’s extensive clinical research network and broad access to the growing Chinese medical market.
Biomaster, which developed its proprietary Cell-Assisted Lipotransfer (CAL) procedure through joint research with the Plastic and Reconstructive Surgery Department at the University of Tokyo’s Graduate School of Medicine, is the only company in Japan authorized to provide stem-cell based therapies to the public.